Please login to the form below

Not currently logged in
Email:
Password:

Czech biotech Sotio selects Chiltern International

UK CRO will work on late-stage trials for its prostate cancer therapy

UK headquartered contract research organisation (CRO) Chiltern International has been appointed by Czech biotech Sotio to carry out phase III clinical trials.

Under the agreement, the CRO will provide full-service management of the phase III trials, entitled Viable, which will involve 126 treatments for 750 prostate cancer patients from across Europe.

The trials will assist the biotech company's development of Active Cellular Immunotherapy (ACI), which focuses on cancer and autoimmune disease treatments - specifically, therapies using an immunotherapy platform based activated dendritic cells.

Chiltern will also be responsible for processing the data obtained during the clinical evaluation.

"I am very pleased that we have been selected to manage this high profile trial," said Chiltern CEO Dr Jim Esinhart.

"I believe it underscores the strengths and expertise of our global oncology therapeutic area team. We look forward to working in close partnership with Sotio deliver a quality outcome."

Viable will be a global clinical trial, tracking a total of 1,170 prostate cancer patients from Europe and the US.

19th March 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Dimitri Azzopardi
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day...
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes....
Interim analysis clinical trials
Assessing the value of interim analyses in clinical trials
Why its important and when its needed...

Infographics